Carmel Diagnostics

Company Overview

Snapshot

Founded in January 2009 by Tzali Cnaani and Sergei Shnizer, Carmel Diagnostics operates with 1–10 employees. The company has raised $6.94 million across 5 funding rounds from 1 investor.

Business overview

Carmel Diagnostics develops a method for measuring oxidative stress (OS) in biological liquids using thermochemiluminescence (TCL) technology, which serves as a key diagnostic parameter and biomarker for health and disease. Its lead product, the Fertissimo TCL Analyzer, is a non-invasive embryo selection system designed for the in-vitro fertilization (IVF) market. This technology aims to enhance IVF success rates by up to 20% and reduce the risk of multiple births through effective embryo viability assessment. The company operates within the Health Tech & Life Sciences sector, specifically targeting digital healthcare and medical devices, and serves laboratories and women in the healthcare and consumer markets.

Strategic signal

In September 2022, Carmel Diagnostics announced its efforts to raise additional funds to commercialize its oxidative stress measurement device. This strategic move, following successful proof-of-concept studies in heart failure risk stratification and embryo selection, signals the company's readiness to transition from clinical validation to market entry, leveraging prior grants from the Israel Innovation Authority and Merck Serono, and a partnership with IVI Valencia.

Company Intelligence Q&A

What is Carmel Diagnostics' primary product for the IVF market?

Carmel Diagnostics' primary product is the Fertissimo TCL Analyzer, a non-invasive embryo selection system for the IVF market. This system uses thermochemiluminescence (TCL) technology to measure oxidative stress in biological liquids, aiming to increase successful IVF pregnancies by up to 20%.

When was Carmel Diagnostics founded and by whom?

Carmel Diagnostics was founded in January 2009 by Tzali Cnaani and Sergei Shnizer.

What was a significant grant received by Carmel Diagnostics in July 2017?

This grant was part of a collaboration with ARAN R&D to complete the development of its non-invasive diagnostic tool for embryo selection in IVF.

What is the core technology developed by Carmel Diagnostics?

Carmel Diagnostics has developed thermochemiluminescence (TCL) technology for measuring oxidative stress (OS) in biological liquids. This technology is applied as a diagnostic parameter for health and disease, particularly in embryo selection for IVF.